Intensity Therapeutics Inc. (NASDAQ: INTS) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT INTENSITY THERAPEUTICS INC.

Intensity Therapeutics Inc. (NASDAQ: INTS)
Listen to this Section


$4.04
-0.0400 ( -0.98% ) 0.1K

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.

Clinical Trial Pipeline Stages


Drug Name Stage
INT230-6DetailsSarcoma Phase 3
INT230-6DetailsBreast cancer Phase 2
INT230-6 w/ KeytrudaDetailsPancreatic cancer, Colorectal cancer Phase 2
INT230-6 w/ YervoyDetailsLiver cancer, Sarcoma, Breast cancer Phase 2

Market Data


Open $4.04
Previous Close $4.08
Volume 0.1K
Market Cap $11.03M
Day Range $4.03 - $4.03
52 Week Range $3.51 - $43.50
Shares Outstanding 2.70M
Change % -0.98%
Net Change ▼ -0.0400
Insider Ownership -0.05%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: Pharmaceutical Preparations
IPO Year2023
CountryUnited States
UnderwriterThe Benchmark Company, Freedom Capital Markets, more

Insider Ownership Transactions

Total Amount Purchased: -770,805.00

Date Type Amount Purchased Purchaser
2024-06-07 Sale -1000.00 Wesolowski John M
2024-05-15 Sale -50000.00 DUBIN THOMAS I H
2024-03-07 Sale -464805.00 BENDER LEWIS H
2024-03-07 Sale -50000.00 Donovan Daniel
2024-03-07 Sale -50000.00 GOLDBERG MARK A
2024-03-07 Sale -50000.00 Leahy Emer
2024-03-07 Sale -25000.00 Wesolowski John M
2023-12-12 Sale -80000.00 Talamo Joseph

SEC Filings


Form Type Description Pages Date
10-q Quarterly Reports 67 Nov 06, 2025
8-k 8K-related 14 Nov 06, 2025
8-k 8K-related 18 Oct 31, 2025
8-k 8K-related 12 Oct 23, 2025
8-k 8K-related 12 Sep 10, 2025
def Proxies and info statements 13 Sep 09, 2025
pre Proxies and info statements 13 Aug 28, 2025
8-k 8K-related 13 Aug 12, 2025
10-q Quarterly Reports 67 Aug 07, 2025
8-k 8K-related 14 Aug 07, 2025

Latest News